The impact of rivastigmine on post‐surgical delirium and cognitive impairment; a randomized clinical trial
International Journal of Geriatric Psychiatry · 2023
DOI: 10.1002/gps.5970 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Geriatric Psychiatry, 2023. Verfasst von Nilofar Massoudi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Clinical Research Development Center, Imam Hossein Educational Hospital, Faculty of Medicine, Shahid Beheshti Universit…. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Delirium. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Themen: Delir
Abstract (Originalsprache)
Background
Delirium is an acute and transient disorder of brain function that often occurs in post‐surgical patients. Rivastigmine is a cholinesterase inhibitor drug that has been proposed as an adjuvant drug in recent years, still, despite significant theoretical evidence, few clinical studies have been performed on its impact on delirium.
Aim
Due to the widespread use of cholinesterase inhibitors in pediatric and adult surgery, the present study aims to investigate the impact of Rivastigmine as a cholinesterase inhibitor on delirium after radical surgery.
Methods
In this randomized double‐blind clinical trial, a hundred recruited patients were randomly assigned to either Rivastigmine (n = 50) or placebo (n = 50) groups, and we measured post‐operative impact on delirium, by Confusion Assessment Method (CAM) score, and cognitive impairment, by the Mini‐Mental State Examination (MMSE). Our univariate and multivariate logistical regression models assessed this hypothesized impact.
Results
Treatment with Rivastigmine was significantly associated with reduced day one post‐op delirium, as measured by CAM score (Odds Ratio (OR) = 0.35, 95% Confidence Interval (CI) 0.11 to 0.97, p = 0.05), and cognitive impairment, as measured by MMSE (OR = 0.25, 95% CI 0.1 to 0.59, p = 0.0022). These associations became stronger after controlling for age, blood loss, and post‐op blood sodium levels: Delirium (OR = 0.23, 95% CI 0.05 to 0.92, p = 0.05), cognitive impairment (OR = 0.12, 95% CI 0.03 to 0.42, p = 0.000178).
Conclusion
The significant result of our randomized clinical trial is that pre‐op Rivastigmine treatment may be associated with a substantial drop in patients experiencing post‐op delirium and post‐op cognitive impairment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Clinical Research Development Center, Imam Hossein Educational Hospital, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Sleep Disorders Center, University of Maryland Medical Center, Baltimore, Maryland, USA.
- Department of Anesthesiology, Critical Care Quality Improvement Research Center at Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Anesthesiology, Anesthesiology Research Center, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Mohsen ArianNik
Zitieren
APA
Massoudi, N., Mohit, B., Fathi, M., Nooraei, N., Hannani, K. K., & ArianNik, M. (2023). The impact of rivastigmine on post‐surgical delirium and cognitive impairment; a randomized clinical trial. International Journal of Geriatric Psychiatry. https://doi.org/10.1002/gps.5970
Vancouver
Massoudi N, Mohit B, Fathi M, Nooraei N, Hannani KK, ArianNik M. The impact of rivastigmine on post‐surgical delirium and cognitive impairment; a randomized clinical trial. International Journal of Geriatric Psychiatry. 2023. doi:10.1002/gps.5970
BibTeX
@article{Massoudi2023,
author = {Massoudi, Nilofar and Mohit, Babak and Fathi, Mohammad and Nooraei, Navid and Hannani, Kia Kazemzadeh and ArianNik, Mohsen},
title = {The impact of rivastigmine on post‐surgical delirium and cognitive impairment; a randomized clinical trial},
journal = {International Journal of Geriatric Psychiatry},
year = {2023},
doi = {10.1002/gps.5970}
}
EUVIMED